Related Experiment Video
Updated: Apr 26, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Reaching low density lipoprotein cholesterol targets
Christos V Rizos1, Fotios Barkas, Moses S Elisaf
1Department of Internal Medicine, School of Medicine, University of Ioannina , Ioannina , Greece.
Insights
Cardiovascular disease management faces challenges as many patients, particularly high-risk individuals, fail to achieve target low-density lipoprotein cholesterol (LDL-C) levels despite available therapies. Addressing multifactorial causes is crucial for improving hyperlipidemia treatment outcomes.
Area of Science:
- Cardiology and lipidology, focusing on cardiovascular disease prevention and management.
Background:
- Cardiovascular disease (CVD) remains a leading global cause of mortality.
- Low-density lipoprotein cholesterol (LDL-C) is a primary target for lipid-lowering therapies due to its strong association with CVD development and progression.
Discussion:
- A significant proportion of patients with hyperlipidemia do not achieve their target LDL-C goals, even with existing treatments.
- Suboptimal achievement of LDL-C targets is frequently observed, especially in high-risk patient populations across different geographical regions.
Key Insights:
- The management of hyperlipidemia is complex, with numerous factors contributing to treatment inertia.
- Current lipid-lowering strategies are insufficient for a substantial number of patients requiring aggressive LDL-C reduction.
Outlook:
- Further research is needed to elucidate the multifactorial reasons behind poor LDL-C goal attainment.
- Implementing targeted strategies to overcome barriers in dyslipidemia management is essential for improving cardiovascular health outcomes.
Abstract:
Cardiovascular disease is a major health problem and within the leading causes of death worldwide. Low-density lipoprotein cholesterol (LDL-C) is strongly associated with the development and progression of cardiovascular disease and is among the main targets of lipid lowering therapy. Despite the various lipid lowering agents for the management of hyperlipidemia, a significant number of patients do not reach their LDL-C target goals. Data from studies in various world regions identify an often poor achievement of LDL-C goals, especially in high risk patient groups. The causes of this suboptimal management of hyperlipidemia are multifactorial and measures should be taken in order to identify and address these shortcomings in dyslipidemia therapy.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Lipids: Dietary Sources and Requirements
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Coronary Artery Disease IV: Preventive Measures
Cholesterol: Significance and Regulation
Considering cholesterol and...

